AVROBIO Inc.

11.55+0.2200+1.94%Vol 13.36K1Y Perf -17.78%
Apr 23rd, 2021 10:17 DELAYED
BID11.53 ASK11.62
Open11.54 Previous Close11.33
Pre-Market- After-Market-
 - -%  - -
Target Price
25.80 
Analyst Rating
Moderate Buy 1.56
Potential %
121.84 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap480.73M 
Earnings Rating
Buy
Price Range Ratio 52W %
11.87 
Earnings Date
6th May 2021

Today's Price Range

11.2111.64

52W Range

9.9423.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
9.47%
1 Month
-4.71%
3 Months
-22.34%
6 Months
-32.07%
1 Year
-17.78%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AVRO11.550.22001.94
AAPL133.191.25000.95
GOOG2 283.2215.30000.67
MSFT258.371.20000.47
XOM55.600.33000.60
WFC43.540.84001.97
JNJ164.67-0.5100-0.31
FB298.762.24000.76
GE13.530.12000.89
JPM149.001.63001.11
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.87-0.7316.09
Q03 2020-0.81-1.01-24.69
Q02 2020-0.76-0.80-5.26
Q01 2020-0.65-0.77-18.46
Q04 2019-0.60-0.72-20.00
Q03 2019-0.59-0.573.39
Q02 2019-0.76-0.6711.84
Q01 2019-0.71-0.72-1.41
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.750.00-
6/2021 QR-0.750.00-
12/2021 FY-3.059.23Positive
12/2022 FY-2.975.41Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.75
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume13.36K
Shares Outstanding41.62M
Trades Count148
Dollar Volume18.15M
Avg. Volume621.65K
Avg. Weekly Volume272.00K
Avg. Monthly Volume415.38K
Avg. Quarterly Volume695.01K

AVROBIO Inc. (NASDAQ: AVRO) stock closed at 11.33 per share at the end of the most recent trading day (a 2.16% change compared to the prior day closing price) with a volume of 260.96K shares and market capitalization of 480.73M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 123 people. AVROBIO Inc. CEO is Geoff Mackay.

The one-year performance of AVROBIO Inc. stock is -17.78%, while year-to-date (YTD) performance is -18.72%. AVRO stock has a five-year performance of %. Its 52-week range is between 9.94 and 23.5, which gives AVRO stock a 52-week price range ratio of 11.87%

AVROBIO Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.69, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -50.75%, a ROC of -55.83% and a ROE of -54.37%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AVROBIO Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.75 for the next earnings report. AVROBIO Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for AVROBIO Inc. is Moderate Buy (1.56), with a target price of $25.8, which is +121.84% compared to the current price. The earnings rating for AVROBIO Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AVROBIO Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AVROBIO Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.77, ATR14 : 0.93, CCI20 : -19.15, Chaikin Money Flow : 0.01, MACD : -0.67, Money Flow Index : 30.55, ROC : -3.08, RSI : 49.95, STOCH (14,3) : 49.64, STOCH RSI : 1.00, UO : 54.06, Williams %R : -50.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AVROBIO Inc. in the last 12-months were: Geoff Mackay (Option Excercise at a value of $41 320), Phillip B. Donenberg (Buy at a value of $23 420)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (62.50 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
1 (12.50 %)
1 (11.11 %)
1 (11.11 %)
Hold
2 (25.00 %)
2 (22.22 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Strong Buy
1.50
Strong Buy
1.28

AVROBIO Inc.

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

CEO: Geoff Mackay

Telephone: +1 617 914-8420

Address: One Kendall Square, Cambridge 02139, MA, US

Number of employees: 123

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

72%28%

Bearish Bullish

54%46%

Bearish Bullish

61%39%

News

Stocktwits